Online inquiry

IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5572MR)

This product GTTS-WQ5572MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5572MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12131MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-004
GTTS-WQ2876MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ10144MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LBR-101
GTTS-WQ13913MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ10980MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ4320MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ5205MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ11959MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLTA3698A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW